Literature DB >> 12591717

Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas.

Mitsutoshi Nakamura1, Munehiro Kishi, Toshisuke Sakaki, Hiroyuki Hashimoto, Hiroyuki Nakase, Keiji Shimada, Eiwa Ishida, Noboru Konishi.   

Abstract

Deletions on the long arm of chromosome 6 (6q) are one of the most common chromosomal alterations in systemic high-grade non-Hodgkin's lymphomas. However, the locations of allelic deletions and their roles have not yet been reported in primary central nervous system lymphomas (PCNSLs), most of which are classed as non-Hodgkin's lymphoma. We thus performed fine loss of heterozygosity (LOH) mapping of 6q in 29 samples of surgically resected PCNSLs using 39 microsatellite markers to identify commonly deleted regions. LOH was found at 1 or more loci at 6q22-23 in 19 samples (66%); furthermore, 18 of these samples shared a deletion in the same small ( approximately 140 kb) region flanked by D6S1030 and D6S1690, a region in which the human R-PTP-kappa gene (PTPRK) is reported to be located. Reverse transcription-PCR analysis of the mRNA from 4 cases with 6q deletions confirmed loss of this gene, and loss of PTPRK expression was observed in 76% (22 of 29) of tumors with immunohistochemistry. In addition, LOH on 6q22-q23 significantly correlated to shorter patient survival (12.8 +/- 4.3 versus 23.4 +/- 3.5 months; P < 0.0001). Our results suggest that a 140-kb deletion located at 6q22-23 may contain the putative tumor suppressor, PTPRK, that appears to be relevant to the pathogenesis and prognosis of PCNSLs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591717

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51.

Authors:  Ellen R McPhail; Mark E Law; Paul A Decker; Brian P O'Neill
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

Review 2.  Tumour suppressor function of protein tyrosine phosphatase receptor-T.

Authors:  Anthony Scott; Zhenghe Wang
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

3.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

4.  Defining the Protein-Protein Interaction Network of the Human Protein Tyrosine Phosphatase Family.

Authors:  Xu Li; Kim My Tran; Kathryn E Aziz; Alexey V Sorokin; Junjie Chen; Wenqi Wang
Journal:  Mol Cell Proteomics       Date:  2016-07-18       Impact factor: 5.911

5.  Identifying genetic loci and spleen gene coexpression networks underlying immunophenotypes in BXD recombinant inbred mice.

Authors:  Rachel M Lynch; Sudhir Naswa; Gary L Rogers; Stephen A Kania; Suchita Das; Elissa J Chesler; Arnold M Saxton; Michael A Langston; Brynn H Voy
Journal:  Physiol Genomics       Date:  2010-02-23       Impact factor: 3.107

6.  The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1.

Authors:  Jeyanthy Eswaran; Judit E Debreczeni; Emma Longman; Alastair J Barr; Stefan Knapp
Journal:  Protein Sci       Date:  2006-05-02       Impact factor: 6.725

Review 7.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

Review 8.  Receptor protein tyrosine phosphatase from stem cells to mature glial cells of the central nervous system.

Authors:  Smaragda Lamprianou; Sheila Harroch
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

9.  Transcriptomal profiling of site-specific Ras signals.

Authors:  Lorena Agudo-Ibáñez; Fátima Núñez; Fernando Calvo; Inmaculada M Berenjeno; Xosé R Bustelo; Piero Crespo
Journal:  Cell Signal       Date:  2007-07-04       Impact factor: 4.315

Review 10.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.